Recent work has also demonstrated that TP53 mutations, a common feature of many high-risk pediatric brain tumors, impairs anti-tumor immunity through down-regulation of MHC-I in pre-clinical models of medulloblastoma and DIPG (107). The gene discussed is TP53; the disease is neoplasm.